News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,380 Results
Type
Article (14264)
Company Profile (281)
Press Release (253835)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79562)
Career Advice (152)
Deals (13233)
Drug Delivery (35)
Drug Development (50482)
Employer Resources (31)
FDA (5739)
Job Trends (5137)
News (144508)
Policy (10036)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21684)
ALS (64)
Alzheimer's disease (849)
Antibody-drug conjugate (ADC) (100)
Approvals (5767)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4563)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (58)
Brain cancer (20)
Breast cancer (155)
Cancer (1482)
Cardiovascular disease (117)
Career advice (133)
Career pathing (2)
CAR-T (117)
Cell therapy (331)
Cervical cancer (8)
Clinical research (41111)
Collaboration (543)
Compensation (260)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1527)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1302)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29861)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48646)
Executive appointments (464)
FDA (6446)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1080)
Grass and pollen (2)
Guidances (26)
Healthcare (6600)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (114)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7274)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (209)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2622)
Medtech (2623)
Mergers & acquisitions (6291)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1260)
NextGen: Class of 2025 (2021)
Non-profit (854)
Now hiring (21)
Obesity (194)
Opinion (103)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (78)
Peanut (35)
People (25659)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14514)
Phase II (19121)
Phase III (12093)
Pipeline (815)
Policy (45)
Postmarket research (854)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8650)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (214)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (96)
Last 7 days (518)
Last 30 days (1521)
Last 365 days (19594)
2025 (6328)
2024 (20563)
2023 (22424)
2022 (26846)
2021 (27821)
2020 (23366)
2019 (16232)
2018 (11751)
2017 (13760)
2016 (11846)
2015 (14361)
2014 (10409)
2013 (7505)
2012 (7544)
2011 (7636)
2010 (7433)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17318)
Australia (2935)
California (3874)
Canada (1142)
China (361)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37281)
Florida (467)
Georgia (117)
Idaho (16)
Illinois (232)
India (10)
Indiana (94)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (477)
Massachusetts (3095)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (972)
New Mexico (12)
New York (1049)
North Carolina (555)
North Dakota (5)
Northern California (1709)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (744)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1492)
Tennessee (25)
Texas (449)
United States (13319)
Utah (54)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,380 Results for "flexion therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors.
July 12, 2021
·
5 min read
Genetown
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference.
September 3, 2021
·
1 min read
Deals
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash.
October 11, 2021
·
21 min read
Business
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.
August 4, 2021
·
14 min read
Genetown
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
Flexion Therapeutics, Inc. announced equity inducement grants to three new employees consisting of 6,315 restricted stock units.
October 1, 2021
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Business
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.
July 29, 2021
·
1 min read
Business
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.
May 12, 2021
·
14 min read
Genetown
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference.
June 14, 2021
·
1 min read
1 of 26,838
Next
